AngioDynamics Ownership
| ANGO Stock | USD 9.40 0.04 0.42% |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 40.7 M | Current Value 40.9 M | Avarage Shares Outstanding 30.2 M | Quarterly Volatility 9.7 M |
AngioDynamics |
AngioDynamics Stock Ownership Analysis
About 85.0% of the company shares are held by institutions such as insurance companies. The book value of AngioDynamics was presently reported as 4.57. The company has Price/Earnings To Growth (PEG) ratio of 1.87. AngioDynamics recorded a loss per share of 5.59. The entity had not issued any dividends in recent years. AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people. For more info on AngioDynamics please contact James Clemmer at 518 795 1400 or go to https://www.angiodynamics.com.Besides selling stocks to institutional investors, AngioDynamics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different AngioDynamics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align AngioDynamics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
AngioDynamics Quarterly Liabilities And Stockholders Equity |
|
AngioDynamics Insider Trades History
About 6.0% of AngioDynamics are currently held by insiders. Unlike AngioDynamics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against AngioDynamics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of AngioDynamics' insider trades
AngioDynamics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AngioDynamics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AngioDynamics backward and forwards among themselves. AngioDynamics' institutional investor refers to the entity that pools money to purchase AngioDynamics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 872 K | State Street Corp | 2024-12-31 | 833.5 K | Citadel Advisors Llc | 2024-12-31 | 815.8 K | Jpmorgan Chase & Co | 2024-12-31 | 807.5 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 527.2 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 521.9 K | Divisadero Street Capital Management, Lp | 2024-12-31 | 514.6 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 476.8 K | Arnhold & S. Bleichroeder Advisers, Llc | 2024-12-31 | 410.3 K | Blackrock Inc | 2024-12-31 | 3.9 M | Systematic Financial Management Lp | 2024-12-31 | 2.5 M |
AngioDynamics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AngioDynamics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AngioDynamics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AngioDynamics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AngioDynamics Outstanding Bonds
AngioDynamics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AngioDynamics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AngioDynamics bonds can be classified according to their maturity, which is the date when AngioDynamics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
AngioDynamics Corporate Filings
| 13th of February 2025 Other Reports | ViewVerify | |
| 5th of February 2025 Other Reports | ViewVerify | |
F4 | 17th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 16th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AngioDynamics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in AngioDynamics Stock, please use our How to Invest in AngioDynamics guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.59) | Revenue Per Share | Quarterly Revenue Growth (0.08) | Return On Assets | Return On Equity |
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine if AngioDynamics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.